Stanford Bio-X IIP Seed Grant — Round 13
Funds Stanford faculty collaborations exploring high-risk interdisciplinary bioscience with translational intent.
The Stanford Bio-X Interdisciplinary Initiatives Program (IIP) Seed Grant funds high-risk, high-reward collaborative research in bioengineering, biosciences, and biomedicine that is too speculative for conventional federal funding at its early stage. Awards provide up to $200,000 per project over two years, with a total pool of approximately $4 million deployed every two years. The programme operates on a biennial cycle: Round 12 was awarded in September 2024, making Round 13 the next expected cycle. Since its launch in 2000, the programme has funded 277 projects, engaging more than 440 faculty across all seven Stanford Schools and generating more than $400 million in downstream external funding — a track record that reflects the programme's role as a seed mechanism for subsequent federal and private investment.
Eligibility is restricted exclusively to Stanford faculty teams; external researchers, companies, and individuals are not eligible. Interdisciplinary collaboration across multiple Stanford Schools is an explicit requirement — proposals from a single investigator or a single department will not be funded. Research must be early-stage and target questions that are not fundable through traditional sources at the time of application. No specific technology readiness level floor is required; the programme deliberately targets the earliest-stage work, corresponding approximately to TRL 1–4.
Competitive proposals demonstrate genuine cross-disciplinary need — the collaboration should be scientifically essential, not merely additive. Applicants whose projects could be framed as clinical translation should consider linking co-PIs from the School of Medicine with colleagues from engineering or the natural sciences schools to satisfy the multi-school requirement. The biennial cadence means that missing Round 13 requires a two-year wait; faculty teams should begin assembling collaborators and drafting specific aims well before the announcement of the next deadline, which has not yet been published.
Early-stage, high-risk collaborative research in bioengineering, biosciences, and biomedicine requiring cross-departmental Stanford faculty teams.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see the timeline